

The following listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-24. (Cancelled):

25. (Currently Amended): A method for treating a HCV ~~Flaviviridae~~ viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to any one of claims 60, 96, 102 and 103 ~~claim 50~~.

26. (Currently Amended): A method according to claim 25, wherein said pharmaceutically acceptable salt is a sodium salt.

27. (Cancelled):

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Cancelled):

32. (Cancelled):

33. (Cancelled):

34. (Cancelled):

35. (Cancelled):

36. (Cancelled):

37. (Cancelled):

38. (Previously Presented): A method according to Claim 64, wherein said compound is a sodium salt.

39. (Cancelled):

40. (Cancelled):

41. (Currently Amended): A method for treating a HCV infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to Claim ~~60~~ 25, further comprising administering at least one additional agent chosen from interferon  $\alpha$ , ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine, and ~~or~~ cyclosporin.

42. (Cancelled):

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):

46. (Cancelled):

47. (Cancelled):

48. (Cancelled):

49. (Cancelled):

50. (Cancelled):

51. (Cancelled):

52. (Cancelled):

53. (Cancelled):

54. (Cancelled):

55. (Cancelled):

56. (Cancelled):

57. (Cancelled):

58. (Cancelled):

59. (Cancelled):

60. (Currently Amended): A compound selected from:

3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

~~3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;~~

3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

and

pharmaceutically acceptable salts thereof.

62. (Cancelled):

63. (Cancelled):

64. (Currently Amended): A method for inhibiting or reducing the activity of ~~HCV a flaviviridae viral~~ polymerase in a host comprising administering to said host a therapeutically effective amount of at least one compound according to any one of claims 60, 96, 102 and 103 ~~claim 60~~.

65. (Cancelled):

66. (Cancelled):

67. (Currently Amended): A pharmaceutical composition comprising at least one compound according to any one of claims 60, 96, 102 and 103 ~~claim 60~~ and at least one pharmaceutically acceptable carrier or excipient.

68. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

69. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

70. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC

ACID, or a pharmaceutically acceptable salt thereof.

71. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

72. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

73. (Cancelled):

74. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

75. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

76. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

77. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

78. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

79. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

80. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

81. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

82. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

83. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

84. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the trans position relative to the amino.

85. (Previously Presented): A compound according to claim 84, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

86. (Previously Presented): A compound according to claim 85, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the amino.

87. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the cis position relative to the amino.

88. (Previously Presented): A compound according to claim 87, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

89. (Previously Presented): A compound according to claim 88, wherein said



compound has a 4-hydroxy-cyclohexyl group attached to the amino.

90. (Previously Presented): A compound according to claim 84, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the monosubstituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.

91. (Previously Presented): A compound according to claim 85, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the monosubstituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.


92. (Previously Presented): A compound according to claim 86, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the monosubstituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.






93. (Previously Presented): A compound according to claim 90, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.

94. (Previously Presented): A compound according to claim 91, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.







95. (Previously Presented): A compound according to claim 92, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.





96. (Previously Presented): A compound according to claim 85, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





97. (Previously Presented): A compound according to claim 96, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





98. (Cancelled):

99. (Cancelled):

100. (Cancelled):

101. (Cancelled):

102. (Previously Presented): A compound according to claim 69, wherein said compound is 3-[(*trans*-4-HYDROXY-CYCLOHEXYL)-(*trans* -4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

103. (Currently Amended): A compound according to claim 69, wherein said compound is 3-[(*cis* ~~*trans*~~-4-HYDROXY-CYCLOHEXYL)-(*trans* ~~*cis*~~-4-METHYL-

CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

104. (New): A method according to Claim 41, further comprising administering at least one additional agent chosen from interferon  $\alpha$  and ribavirin.

105. (New): A composition according to claim 67, wherein said compound is a sodium salt.

106. (New): A compound according to any one of claims any one of claims 60, 96, 102 and 103, wherein said compound is a sodium salt.

107. (New): A method according to Claim 25, wherein said HCV of genotype 1b.